Contents
📝 Chapteṛ 1: The Nuṛsing Pṛocess and Patient-Centeṛed Caṛe ....................................................................................... 3
📝 Chapteṛ 2: Dṛug Development and Ethical Consideṛations ........................................................................................ 17
📝 Chapteṛ 3: Phaṛmacoḳinetics and Phaṛmacodynamics ............................................................................................... 29
📝 Chapteṛ 4: Phaṛmacogenetics .......................................................................................................................................... 41
📝 Chapteṛ 5: Complementaṛy and Alteṛnative Theṛapies .............................................................................................. 52
📝 Chapteṛ 6: Pediatṛic Consideṛations – Test Banḳ ........................................................................................................ 63
📝 Chapteṛ 7: Geṛiatṛic Consideṛations – Test Banḳ ........................................................................................................ 74
📝 Chapteṛ 8: Dṛugs in Substance Use Disoṛdeṛ – Test Banḳ .......................................................................................... 85
📝 Chapteṛ 9: Safety and Quality – Test Banḳ .................................................................................................................. 97
📝 Chapteṛ 10: Dṛug Administṛation – Test Banḳ .......................................................................................................... 108
📝 Chapteṛ 11: Dṛug Calculations – Test Banḳ ............................................................................................................... 120
📝 Chapteṛ 12: Fluid Volume and Electṛolytes – Test Banḳ .......................................................................................... 131
📝 Chapteṛ 13: Vitamin and Mineṛal Ṛeplacement – Test Banḳ ................................................................................... 141
📝 Chapteṛ 14: Nutṛitional Suppoṛt – Test Banḳ ............................................................................................................ 152
📝 Chapteṛ 15: Adṛeneṛgic Agonists and Antagonists – Test Banḳ ............................................................................... 164
📝 Chapteṛ 16: Cholineṛgic Agonists and Antagonists – Test Banḳ .............................................................................. 175
📝 Chapteṛ 17: Stimulants – Test Banḳ............................................................................................................................ 186
📝 Chapteṛ 18: Depṛessants – Test Banḳ ............................................................................................................................. 197
📝 Chapteṛ 19: Antiseizuṛe Dṛugs – Test Banḳ ............................................................................................................... 206
📝 Chapteṛ 20: Dṛugs foṛ Paṛḳinsonism and Alzheimeṛ’s Disease – Test Banḳ .................................................................... 214
📝 Chapteṛ 22: Antipsychotics and Anxiolytics .................................................................................................................... 237
📝 Chapteṛ 29: HIV- and AIDS-Ṛelated Dṛugs ............................................................................................................... 312
📝 Chapteṛ 30: Tṛansplant Dṛugs ..................................................................................................................................... 322
📝 Chapteṛ 31: Vaccines .................................................................................................................................................... 332
📝 Chapteṛ 32: Anticanceṛ Dṛugs ..................................................................................................................................... 343
📝 Chapteṛ 33: Taṛgeted Theṛapies to Tṛeat Canceṛ ...................................................................................................... 350
📝 Chapteṛ 11: Dṛug Calculations .................................................................................................................................... 364
📝 Chapteṛ 12: Fluid Volume and Electṛolytes................................................................................................................ 374
📝 Chapteṛ 13: Vitamin and Mineṛal Ṛeplacement ........................................................................................................ 385
📝 Chapteṛ 14: Nutṛitional Suppoṛt ................................................................................................................................. 395
📝 Chapteṛ 15: Adṛeneṛgic Agonists and Antagonists .................................................................................................... 407
📝 Chapteṛ 16: Cholineṛgic Agonists and Antagonists ......................................................................................................... 417
📝 Chapteṛ 17: Stimulants ................................................................................................................................................... 429
📝 Chapteṛ 18: Depṛessants ................................................................................................................................................ 441
1
,📝 Chapteṛ 19: Antiseizuṛe Dṛugs ........................................................................................................................................ 452
📝 Chapteṛ 20: Dṛugs foṛ Paṛḳinsonism and Alzheimeṛ’s Disease ....................................................................................... 464
📝 Chapteṛ 21: Dṛugs foṛ Neuṛomusculaṛ Disoṛdeṛs and Muscle Spasms ........................................................................... 473
📝 Chapteṛ 22: Antipsychotics and Anxiolytics .................................................................................................................... 485
📝 Chapteṛ 23: Antidepṛessants and Mood Stabilizeṛs ....................................................................................................... 498
📝 Chapteṛ 24: Antiinflammatoṛies .................................................................................................................................... 508
📝 Chapteṛ 25: Analgesics ................................................................................................................................................... 516
📝 Chapteṛ 26: Antibacteṛials .............................................................................................................................................. 527
📝 Chapteṛ 27: Antitubeṛculaṛs, Antifungals, and Antiviṛals ............................................................................................... 535
📝 Chapteṛ 28: Antimalaṛials, Anthelmintics, and Peptides ................................................................................................ 544
📝 Chapteṛ 29: HIV- and AIDS-Ṛelated Dṛugs ...................................................................................................................... 553
📝 Chapteṛ 30: Tṛansplant Dṛugs ......................................................................................................................................... 562
📝 Chapteṛ 31: Vaccines ...................................................................................................................................................... 572
📝 Chapteṛ 32: Anticanceṛ Dṛugs......................................................................................................................................... 580
📝 Chapteṛ 33: Taṛgeted Theṛapies to Tṛeat Canceṛ ........................................................................................................... 589
📝 Chapteṛ 35: Uppeṛ Ṛespiṛatoṛy Disoṛdeṛs ...................................................................................................................... 599
📝 Chapteṛ 36: Loweṛ Ṛespiṛatoṛy Disoṛdeṛs ...................................................................................................................... 609
📝 Chapteṛ 37: Caṛdiac Glycosides, Antianginals, and Antidysṛhythmics ............................................................................ 618
📝 Chapteṛ 38: Diuṛetics ...................................................................................................................................................... 628
📝 Chapteṛ 39: Antihypeṛtensives ....................................................................................................................................... 638
📝 Chapteṛ 40: Anticoagulants, Antiplatelets, and Thṛombolytics ...................................................................................... 648
📝 Chapteṛ 41: Antihypeṛlipidemics and Dṛugs to Impṛove Peṛipheṛal Blood Flow ............................................................ 657
📝 Chapteṛ 42: Gastṛointestinal Tṛact Disoṛdeṛs ................................................................................................................. 667
📝 Chapteṛ 43: Antiulceṛ Dṛugs ........................................................................................................................................... 677
📝 Chapteṛ 44: Eye and Eaṛ Disoṛdeṛs ................................................................................................................................. 686
📝 Chapteṛ 45: Deṛmatologic Disoṛdeṛs .............................................................................................................................. 697
📝 Chapteṛ 46: Pituitaṛy, Thyṛoid, Paṛathyṛoid, and Adṛenal Disoṛdeṛs .............................................................................. 707
📝 Chapteṛ 47: Antidiabetics ............................................................................................................................................... 718
📝 Chapteṛ 48: Uṛinaṛy Disoṛdeṛs ........................................................................................................................................ 729
📝 Chapteṛ 49: Pṛegnancy and Pṛeteṛm Laboṛ .................................................................................................................... 740
📝 Chapteṛ 50: Laboṛ, Deliveṛy, and Postpaṛtum ................................................................................................................ 749
📝 Chapteṛ 51: Neonatal and Newboṛn .............................................................................................................................. 761
📝 Chapteṛ 52: Ṛepṛoductive Health ................................................................................................................................... 770
📝 Chapteṛ 53: Men’s Health and Ṛepṛoductive Disoṛdeṛs ................................................................................................. 779
📝 Chapteṛ 54: Sexually Tṛansmitted Infections .................................................................................................................. 791
2
,📝 Chapter 1: The Nursing Process and Patient-Centered Care
Test Bank — 28 Advanced University-Level Multiple Choice Questions
Question 1
A nurse is assessing a patient’s readiness to learn about a newly prescribed
antihypertensive medication. Which phase of the nursing process does this
action represent?
A. Assessment
B. Diagnosis
C. Planning
D. Evaluation
✅ Correct Answer: A. Assessment
Rationale:
The assessment phase involves collecting both subjective and objective data,
including the patient's readiness to learn. Evaluating factors such as
motivation, learning preferences, and potential barriers occurs during this
initial phase and guides the rest of the nursing process.
Question 2
In the planning phase of the nursing process, which goal is written correctly
according to SMART criteria?
A. The patient will understand medication use.
B. The patient will take medications correctly.
C. The patient will verbalize proper medication use by discharge.
D. The patient will verbalize the purpose and side effects of atenolol by the
end of the teaching session.
3
, ✅ Correct Answer: D. The patient will verbalize the purpose and side
effects of atenolol by the end of the teaching session.
Rationale:
SMART goals are Specific, Measurable, Achievable, Realistic, and Time-
bound. Option D satisfies all five criteria. The other options lack specificity
and/or measurability.
Question 3
Which nursing diagnosis is appropriate for a patient newly prescribed an
insulin pen who expresses anxiety about self-injection?
A. Risk for unstable blood glucose level
B. Deficient knowledge related to insulin administration
C. Noncompliance with prescribed therapy
D. Anxiety related to perceived difficulty in self-injection
✅ Correct Answer: D. Anxiety related to perceived difficulty in self-
injection
Rationale:
The patient's expressed fear of injecting indicates an emotional response,
which supports an "Anxiety" diagnosis. The other options don't align as
closely with the patient's stated concern.
Question 4
Which intervention best represents the “implementation” phase of the nursing
process in pharmacologic care?
A. Teaching the patient about possible side effects of a beta-blocker
B. Monitoring blood pressure post-medication administration
C. Setting a goal for medication adherence
D. Documenting the effectiveness of pain medication
4
📝 Chapteṛ 1: The Nuṛsing Pṛocess and Patient-Centeṛed Caṛe ....................................................................................... 3
📝 Chapteṛ 2: Dṛug Development and Ethical Consideṛations ........................................................................................ 17
📝 Chapteṛ 3: Phaṛmacoḳinetics and Phaṛmacodynamics ............................................................................................... 29
📝 Chapteṛ 4: Phaṛmacogenetics .......................................................................................................................................... 41
📝 Chapteṛ 5: Complementaṛy and Alteṛnative Theṛapies .............................................................................................. 52
📝 Chapteṛ 6: Pediatṛic Consideṛations – Test Banḳ ........................................................................................................ 63
📝 Chapteṛ 7: Geṛiatṛic Consideṛations – Test Banḳ ........................................................................................................ 74
📝 Chapteṛ 8: Dṛugs in Substance Use Disoṛdeṛ – Test Banḳ .......................................................................................... 85
📝 Chapteṛ 9: Safety and Quality – Test Banḳ .................................................................................................................. 97
📝 Chapteṛ 10: Dṛug Administṛation – Test Banḳ .......................................................................................................... 108
📝 Chapteṛ 11: Dṛug Calculations – Test Banḳ ............................................................................................................... 120
📝 Chapteṛ 12: Fluid Volume and Electṛolytes – Test Banḳ .......................................................................................... 131
📝 Chapteṛ 13: Vitamin and Mineṛal Ṛeplacement – Test Banḳ ................................................................................... 141
📝 Chapteṛ 14: Nutṛitional Suppoṛt – Test Banḳ ............................................................................................................ 152
📝 Chapteṛ 15: Adṛeneṛgic Agonists and Antagonists – Test Banḳ ............................................................................... 164
📝 Chapteṛ 16: Cholineṛgic Agonists and Antagonists – Test Banḳ .............................................................................. 175
📝 Chapteṛ 17: Stimulants – Test Banḳ............................................................................................................................ 186
📝 Chapteṛ 18: Depṛessants – Test Banḳ ............................................................................................................................. 197
📝 Chapteṛ 19: Antiseizuṛe Dṛugs – Test Banḳ ............................................................................................................... 206
📝 Chapteṛ 20: Dṛugs foṛ Paṛḳinsonism and Alzheimeṛ’s Disease – Test Banḳ .................................................................... 214
📝 Chapteṛ 22: Antipsychotics and Anxiolytics .................................................................................................................... 237
📝 Chapteṛ 29: HIV- and AIDS-Ṛelated Dṛugs ............................................................................................................... 312
📝 Chapteṛ 30: Tṛansplant Dṛugs ..................................................................................................................................... 322
📝 Chapteṛ 31: Vaccines .................................................................................................................................................... 332
📝 Chapteṛ 32: Anticanceṛ Dṛugs ..................................................................................................................................... 343
📝 Chapteṛ 33: Taṛgeted Theṛapies to Tṛeat Canceṛ ...................................................................................................... 350
📝 Chapteṛ 11: Dṛug Calculations .................................................................................................................................... 364
📝 Chapteṛ 12: Fluid Volume and Electṛolytes................................................................................................................ 374
📝 Chapteṛ 13: Vitamin and Mineṛal Ṛeplacement ........................................................................................................ 385
📝 Chapteṛ 14: Nutṛitional Suppoṛt ................................................................................................................................. 395
📝 Chapteṛ 15: Adṛeneṛgic Agonists and Antagonists .................................................................................................... 407
📝 Chapteṛ 16: Cholineṛgic Agonists and Antagonists ......................................................................................................... 417
📝 Chapteṛ 17: Stimulants ................................................................................................................................................... 429
📝 Chapteṛ 18: Depṛessants ................................................................................................................................................ 441
1
,📝 Chapteṛ 19: Antiseizuṛe Dṛugs ........................................................................................................................................ 452
📝 Chapteṛ 20: Dṛugs foṛ Paṛḳinsonism and Alzheimeṛ’s Disease ....................................................................................... 464
📝 Chapteṛ 21: Dṛugs foṛ Neuṛomusculaṛ Disoṛdeṛs and Muscle Spasms ........................................................................... 473
📝 Chapteṛ 22: Antipsychotics and Anxiolytics .................................................................................................................... 485
📝 Chapteṛ 23: Antidepṛessants and Mood Stabilizeṛs ....................................................................................................... 498
📝 Chapteṛ 24: Antiinflammatoṛies .................................................................................................................................... 508
📝 Chapteṛ 25: Analgesics ................................................................................................................................................... 516
📝 Chapteṛ 26: Antibacteṛials .............................................................................................................................................. 527
📝 Chapteṛ 27: Antitubeṛculaṛs, Antifungals, and Antiviṛals ............................................................................................... 535
📝 Chapteṛ 28: Antimalaṛials, Anthelmintics, and Peptides ................................................................................................ 544
📝 Chapteṛ 29: HIV- and AIDS-Ṛelated Dṛugs ...................................................................................................................... 553
📝 Chapteṛ 30: Tṛansplant Dṛugs ......................................................................................................................................... 562
📝 Chapteṛ 31: Vaccines ...................................................................................................................................................... 572
📝 Chapteṛ 32: Anticanceṛ Dṛugs......................................................................................................................................... 580
📝 Chapteṛ 33: Taṛgeted Theṛapies to Tṛeat Canceṛ ........................................................................................................... 589
📝 Chapteṛ 35: Uppeṛ Ṛespiṛatoṛy Disoṛdeṛs ...................................................................................................................... 599
📝 Chapteṛ 36: Loweṛ Ṛespiṛatoṛy Disoṛdeṛs ...................................................................................................................... 609
📝 Chapteṛ 37: Caṛdiac Glycosides, Antianginals, and Antidysṛhythmics ............................................................................ 618
📝 Chapteṛ 38: Diuṛetics ...................................................................................................................................................... 628
📝 Chapteṛ 39: Antihypeṛtensives ....................................................................................................................................... 638
📝 Chapteṛ 40: Anticoagulants, Antiplatelets, and Thṛombolytics ...................................................................................... 648
📝 Chapteṛ 41: Antihypeṛlipidemics and Dṛugs to Impṛove Peṛipheṛal Blood Flow ............................................................ 657
📝 Chapteṛ 42: Gastṛointestinal Tṛact Disoṛdeṛs ................................................................................................................. 667
📝 Chapteṛ 43: Antiulceṛ Dṛugs ........................................................................................................................................... 677
📝 Chapteṛ 44: Eye and Eaṛ Disoṛdeṛs ................................................................................................................................. 686
📝 Chapteṛ 45: Deṛmatologic Disoṛdeṛs .............................................................................................................................. 697
📝 Chapteṛ 46: Pituitaṛy, Thyṛoid, Paṛathyṛoid, and Adṛenal Disoṛdeṛs .............................................................................. 707
📝 Chapteṛ 47: Antidiabetics ............................................................................................................................................... 718
📝 Chapteṛ 48: Uṛinaṛy Disoṛdeṛs ........................................................................................................................................ 729
📝 Chapteṛ 49: Pṛegnancy and Pṛeteṛm Laboṛ .................................................................................................................... 740
📝 Chapteṛ 50: Laboṛ, Deliveṛy, and Postpaṛtum ................................................................................................................ 749
📝 Chapteṛ 51: Neonatal and Newboṛn .............................................................................................................................. 761
📝 Chapteṛ 52: Ṛepṛoductive Health ................................................................................................................................... 770
📝 Chapteṛ 53: Men’s Health and Ṛepṛoductive Disoṛdeṛs ................................................................................................. 779
📝 Chapteṛ 54: Sexually Tṛansmitted Infections .................................................................................................................. 791
2
,📝 Chapter 1: The Nursing Process and Patient-Centered Care
Test Bank — 28 Advanced University-Level Multiple Choice Questions
Question 1
A nurse is assessing a patient’s readiness to learn about a newly prescribed
antihypertensive medication. Which phase of the nursing process does this
action represent?
A. Assessment
B. Diagnosis
C. Planning
D. Evaluation
✅ Correct Answer: A. Assessment
Rationale:
The assessment phase involves collecting both subjective and objective data,
including the patient's readiness to learn. Evaluating factors such as
motivation, learning preferences, and potential barriers occurs during this
initial phase and guides the rest of the nursing process.
Question 2
In the planning phase of the nursing process, which goal is written correctly
according to SMART criteria?
A. The patient will understand medication use.
B. The patient will take medications correctly.
C. The patient will verbalize proper medication use by discharge.
D. The patient will verbalize the purpose and side effects of atenolol by the
end of the teaching session.
3
, ✅ Correct Answer: D. The patient will verbalize the purpose and side
effects of atenolol by the end of the teaching session.
Rationale:
SMART goals are Specific, Measurable, Achievable, Realistic, and Time-
bound. Option D satisfies all five criteria. The other options lack specificity
and/or measurability.
Question 3
Which nursing diagnosis is appropriate for a patient newly prescribed an
insulin pen who expresses anxiety about self-injection?
A. Risk for unstable blood glucose level
B. Deficient knowledge related to insulin administration
C. Noncompliance with prescribed therapy
D. Anxiety related to perceived difficulty in self-injection
✅ Correct Answer: D. Anxiety related to perceived difficulty in self-
injection
Rationale:
The patient's expressed fear of injecting indicates an emotional response,
which supports an "Anxiety" diagnosis. The other options don't align as
closely with the patient's stated concern.
Question 4
Which intervention best represents the “implementation” phase of the nursing
process in pharmacologic care?
A. Teaching the patient about possible side effects of a beta-blocker
B. Monitoring blood pressure post-medication administration
C. Setting a goal for medication adherence
D. Documenting the effectiveness of pain medication
4
